Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-24

Clinical Trial Update: Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating guselkumab for pityriasis rubra pilaris has completed and results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Guselkumab (guselkumab)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Pityriasis Rubra Pilaris | Phase 2 | Status: COMPLETED | Results posted: 2024-05-24